How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,817 results for

Thromboembolic Disease in Pregnancy


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Incidence and risk factors of venous thromboembolism during postpartum-period: a population-based cohort-study. (Abstract)

, primiparity, cesarean section, cardiac/renal diseases, and varicose veins were associated with an increased risk for postpartum venous thromboembolic events. The risk remained elevated for 180 days in women with thrombophilia, cesarean section, multiple pregnancy, varicose veins, and cardiac disease.The risk of venous thromboembolic events remained elevated compared with that of the nonpregnant women after the usually defined postpartum period (6 weeks). The results might assist in selecting women in need (...) , declining to two-fold immediately after that. Almost half of the venous thromboembolic events occurred between 43 and 180 days postpartum. The incidence of venous thromboembolic events was four-fold compared with that of nonpregnant women. Three venous thromboembolic events-related deaths occurred. Older age, higher body mass index, thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, in vitro fertilization with ovarian hyperstimulation

2017 Acta Obstetricia et Gynecologica Scandinavica

82. Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. (Full text)

/recent hospitalization with/without surgery, nursing home confinement, active cancer, trauma/fracture, leg paresis, prior superficial vein thrombosis, transvenous catheter/pacemaker, ischemic heart disease, congestive heart failure, chronic lung or renal disease, serious liver disease, asthma, diabetes mellitus, hormone therapy, and pregnancy/postpartum.A total of 513 cases (39.4%) and 189 controls (12.7%) had an infection in the previous 92 days (odds ratio, 4.5; 95% confidence interval, 3.6-5.5; P (...) Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. The independent association of recent infection with venous thromboembolism is uncertain. The study aims were to test both overall infection (site unspecified) and specific infection sites as potential risk factors for deep vein thrombosis and pulmonary embolism adjusting for other known venous thromboembolism factors.By using Rochester Epidemiology Project resources, we identified all

2017 American Journal of Medicine PubMed abstract

83. Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

lung cancer and elevated D-dimer. Condition or disease Intervention/treatment Phase Venous Thromboembolism Lung Neoplasm Drug: Tinzaparin Sodium Phase 3 Detailed Description: Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place (...) table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Assistance Publique - Hôpitaux de Paris: Low-molecular-weight Heparin Tinzaparin Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Lung Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases

2017 Clinical Trials

84. Thrombosis Outcomes in Pediatric Venous Thromboembolism

biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic syndrome and post PE impairment ) after an initial VTE with those that do not develop such outcomes. Condition or disease Venous Thromboembolism Detailed Description: All newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at Children's Medical Center, Dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored (...) malignancy Pregnancy or immediate post-partum period (12 weeks after delivery) Sickle cell disease Known bleeding disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT03068923 Contacts Layout table for location contacts Contact: Kendra Malone, MPH

2017 Clinical Trials

85. Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Posted : October 26, 2018 See Sponsor: Fadoi Foundation, Italy Collaborator: University of Perugia, Italy Information provided by (Responsible Party): Fadoi Foundation, Italy Study Details Study Description Go to Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Dalteparin Phase 3 Study Design Go (...) Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

86. Nausea/vomiting in pregnancy

examination. Goitre. Conditions causing nausea and vomiting in pregnancy: Genito-urinary conditions — urinary tract infection, uraemia, pyelonephritis, ovarian torsion, renal stones. Metabolic disorders and endocrine conditions — hypercalcaemia, thyrotoxicosis, diabetic ketoacidosis, Addison's disease. Gastrointestinal conditions — gastritis, gastroenteritis, peptic ulcer, pancreatitis, cholecystitis, bowel obstruction, hepatitis, cholelithiasis, appendicitis. Neurological disorders — vestibular disease (...) Nausea/vomiting in pregnancy Nausea/vomiting in pregnancy - NICE CKS Share Nausea/vomiting in pregnancy: Summary The majority of women vomit or feel nauseated in early pregnancy. Symptoms usually begin between the fourth and seventh weeks of gestation and usually resolve around the 20th week of pregnancy. Hyperemesis gravidarum is a diagnosis of exclusion characterized by prolonged and severe nausea and vomiting, dehydration, electrolyte imbalance, ketonuria, and body weight loss of more than 5

2018 NICE Clinical Knowledge Summaries

87. Pregnancy and venous thromboembolism. (Abstract)

Pregnancy and venous thromboembolism. This review provides a concise and complete overview of diagnostic work-up and treatment of venous thromboembolism in pregnancy, with attention to recent research developments and recent applicable guidelines. This may be useful for all the players of the multidisciplinary interaction needed in this disease management, namely cardiologists and gynecological/obstetric teams.Venous thromboembolism is, in the developed world, a major cause of maternal (...) and watchful eyes, deciding on a case-to-case and actively contributing in reducing pregnancy-related morbidity.Although there is an ongoing debate on various aspects of this condition and there is a paucity of high-quality studies, this review attempts to simplify the complex aspects of joining safety and efficacy in diagnosing and treating a possible two-people life-threatening disease.

2014 Current Opinion in Obstetrics and Gynecology

88. Flowchart: Management of hypertension in pregnancy

investigations and fetal assessment Birth Inpatient or outpatient care Worsening maternal or fetal condition? Is birth indicated? Yes No No Yes Risk factors for preeclampsia • Previous history of preeclampsia • Family history of preeclampsia • Inter-pregnancy interval > 10 years • Nulliparity • Pre-existing medical conditions o APLS o Pre-existing diabetes o Renal disease o Chronic hypertension o Chronic autoimmune disease • Age > 40 years • BMI > 35 kg/m 2 • Multiple pregnancy • Elevated BP at booking (...) Flowchart: Management of hypertension in pregnancy Queensland Health State of Queensland (Queensland Health) 2016 Queensland Clinical Guidelines, Queensland Clinical Guidelines Management of hypertension in pregnancy Queensland Clinical Guidelines: Hypertensive disorders in pregnancy. Flowchart version: F15.13-2-V7-R20 Hypertension sBP = 140 mmHg and/or dBP = 90 mmHg Maternal

2016 Queensland Health

89. Hypertensive disorders of pregnancy

stable then every 30 minutes • Respiratory rate and patellar reflexes hourly • Temperature 2nd hourly • Continuous CTG monitoring if > 24 weeks (interpret with caution if : greater than, 10 years • Nulliparity • Pre-existing medical conditions o APLS o Pre-existing diabetes o Renal disease o Chronic hypertension o Chronic autoimmune disease • Age > 40 years • BMI > 35 kg/m 2 • Multiple pregnancy • Elevated BP at booking • Gestational trophoblastic disease • Fetal triploidy Maternal investigations (...) USS Ultrasound scan VTE Venous thromboembolism Definition of terms Expectant management Refers to prolongation of the pregnancy beyond 48 hours with maternal and fetal monitoring. 1 Multidisciplinary team May include as relevant to the clinical circumstances obstetrician, midwives, obstetric physician, anaesthetist, neonatologist/paediatrician experienced in the care of women with hypertension in pregnancy. Obstetrician Local facilities may differentiate the roles and responsibilities assigned

2016 Queensland Health

90. Guidelines for Weight Gain During Pregnancy: A Focused Practice Question

be gained during pregnancy. The search included: Turning Research into Practice (TRIP) database, National Guideline Clearinghouse, National Institute for Health Care Excellence (NICE), Society of Obstetricians and Gynaecologists of Canada (SOGC), Health Canada, Public Health Agency of Canada, Public Health Ontario, Centers for Disease Control and Prevention (CDC), Institute of Medicine, and the World Health Organization. The search was completed in November 2015 and is outlined in Appendix A. 4 (...) dystocia, caesarean section and thromboembolism. Refer to the data extraction table in Appendix C for further information regarding the SOGC guideline. 7 8. Synthesis of Findings ? The recommended amount of weight that a woman gains during her pregnancy is a range that is based on her pre-pregnancy body mass index (BMI). ? For women with a normal weight, 11.5 - 16 kg (25-35 lbs) is the recommended weight gain during pregnancy. ? These ranges are applicable to all women with singleton pregnancies

2016 Peel Health Library

91. Anaemia and iron deficiency in pregnancy and postpartum

for the Global Burden of Disease Study 2013. Lancet 2014;384:980-1004. (44) Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol 2012;91:143-154. Anaemia, iron deficiency and pregnancy 2016 51 (45) Khalafallah AA, Dennis AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy 2012;2012:630519. (46) Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R. Expert recommendations for the diagnosis (...) -2012 (60) Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1-29. (61) WHO. Iron Deficiency Anaemia: Assessment, prevention and control. (62) Good Clinical Practice Recommendations for Iron Deficiency Anemia in Pregnancy (IDA) in Pregnancy in India. The Journal of Obstetrics and Gynecology of India 2011;61:569-571. (63) Dudrick SJ, O'Donnell JJ, Matheny RG, Unkel SP, Raleigh DP. Stimulation

2016 Nordic Federation of Societies of Obstetrics and Gynecology

92. IBD: Pregnancy

IBD: Pregnancy CONSENSUS STATEMENT The Toronto Consensus Statements for the Management of In?ammatory Bowel Disease in Pregnancy Geoffrey C.Nguyen, 1, *CynthiaH.Seow, 2, * Cynthia Maxwell, 3 Vivian Huang, 4 Yvette Leung, 5 Jennifer Jones, 6 Grigorios I. Leontiadis, 7 Frances Tse, 7 Uma Mahadevan, 8 and C. Janneke van der Woude, 9 on behalf of the IBD in Pregnancy Consensus Group 1 Mount Sinai Hospital Centre for In?ammatory Bowel Disease, Department of Medicine, and 3 Department of Obstetrics (...) , San Francisco, San Francisco, California; and 9 Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands BACKGROUND & AIMS: The management of in?ammatory bowel disease (IBD) poses a particular challenge during preg- nancybecausethehealthofboththemotherandthefetusmust be considered. METHODS: A systematic literature search identi?ed studies on the management of IBD during pregnancy. The quality of evidence and strength of recommendations were rated

2016 Canadian Association of Gastroenterology

93. Management of systemic lupus erythematosus during pregnancy: challenges and solutions (Full text)

Management of systemic lupus erythematosus during pregnancy: challenges and solutions Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease predominantly affecting women, particularly those of childbearing age. SLE provides challenges in the prepregnancy, antenatal, intrapartum, and postpartum periods for these women, and for the medical, obstetric, and midwifery teams who provide their care. As with many medical conditions in pregnancy, the best maternal and fetal (...) -neonatal outcomes are obtained with a planned pregnancy and a cohesive multidisciplinary approach. Effective prepregnancy risk assessment and counseling includes exploration of factors for poor pregnancy outcome, discussion of risks, and appropriate planning for pregnancy, with consideration of discussion of relative contraindications to pregnancy. In pregnancy, early referral for hospital-coordinated care, involvement of obstetricians and rheumatologists (and other specialists as required

2017 Open access rheumatology : research and reviews PubMed abstract

94. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD (Full text)

Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter (...) Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article Navigation Article Contents Article Navigation 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Francesco Cosentino ESC Chairperson Sweden

2019 European Society of Cardiology PubMed abstract

95. Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. (Full text)

Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. We describe the findings from a national study of maternal and fetal outcomes of pregnancy in women with sickle cell disease (SCD). Data were collected via the United Kingdom Obstetric Surveillance System between 1 February 2010 and 31 January 2011 from 109 women, of whom 51 (46·8%) had HbSS and 44 (40·4%) had HbSC. Data included antenatal, maternal (...) and fetal outcomes. Comparisons were made between women with HbSS and HbSC. Incidence of complications were acute pain (57%), blood transfusion (26%), urinary tract infection (UTI; 12%) and critical care unit admission (23%) and these were all more common in women with HbSS than HbSC. There was no difference in the incidence of acute chest syndrome, hypertension and venous thromboembolism between HbSS and HbSC. Women with HbSS were more likely to deliver at <37 weeks gestation (P = 0·01

2015 British journal of haematology PubMed abstract

96. Obesity in pregnancy

(Gestational diabetes mellitus and Diabetes in Pregnancy ) 14 • Preeclampsia 14 • Obstructive sleep apnoea—may be related to adverse fetal outcomes 14 • Thromboembolic disease 14 • Cholecystitis 14 • Depression 4 • Difficulties with abdominal palpitation and obtaining adequate auscultation of fetal heart and cardiotocograph (CTG) • Suboptimal ultrasonography 5 • Diagnosis of congenital abnormality 17 • Preterm birth (PTB)—mostly associated with comorbidities 14,18 • Increased odds of dizygous twinning 19 (...) • Haemorrhage 14 • Chest, genital tract, wound and urinary infections 14 • Reduced rate of breastfeeding 14 • Postnatal depression 27 • Thromboembolic disease Neonatal/ childhood • Admission to neonatal intensive care units 14 • Macrosomia 14 • Congenital malformations 17 • Obesity 14 and metabolic syndrome 28 • Neurodevelopmental disorders (e.g. autism, developmental delays) 29 • Asthma 30 Queensland Clinical Guideline: Obesity in pregnancy Refer to online version, destroy printed copies after use Page 10

2015 Queensland Health

97. Management of AML in Pregnancy

pregnancy should be managed jointly by consultant haematologists, obstetricians, anaesthetists and neonatologists. Consideration should be given to the health of both mother and baby and the informed wishes of the mother. The woman should be fully informed about the diagnosis, treatment of the disease and possible complications during pregnancy. Treatment delays may compromise maternal outcome without improving the outcome for the foetus (Greenlund et al , ). Without treatment, maternal death can occur (...) . & Chapman, S.W. ( 1998 ) Antifungal therapy during pregnancy . Clinical Infectious Diseases , 27 , 1151 – 1160 . Lynch, C.M. , Sinnott, J.T. , Holt, D.A. & Herold, A.H. ( 1991 ) Use of antibiotics during pregnancy . American Family Physician , 43 , 1365 – 1368 . Meyer‐Wittkopf, M. , Barth, H. , Emons, G. & Schmidt, S. ( 2001 ) Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature . Ultrasound in Obstetrics & Gynecology , 18

2015 British Committee for Standards in Haematology

98. Management of Beta Thalassaemia in Pregnancy

for liver iron, cardiac iron and fructosamine ? thalassaemia intermedia pregnancy outcomes, especially indications for transfusion, management of maternal anaemia in nontransfused patients and FGR ? compliance with prophylaxis against venous thromboembolic disease in women who have undergone splenectomy. Evidence level 4 Evidence level 4 Evidence level 1++ D PReferences 1. Ryan K, Bain BJ, Worthington D, James J, Plews D, Mason A, et al.; British Committee for Standards in Haemotology. Significant (...) T. Outcomes of pregnancies complicated by beta-thalassemia/hemoglobin E disease. Int J Gynaecol Obstet 2009;104:203–5. 46. Bajoria R, Chatterjee R. Current perspectives of fertility and pregnancy in thalassemia. Hemoglobin 2009;33 Suppl 1:S131–5. 47. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36–43. 48. Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in ß-thalassemia: a status quo. Expert Rev Hematol 2012;5:505–11. 49. Anderson LJ

2014 Royal College of Obstetricians and Gynaecologists

99. SMFM State of Pregnancy Monograph

physicians and scientists is dedicated to the optimization of pregnancy and perinatal outcomes. SMFM’s mission is to improve maternal and child outcomes, raising the standards of prevention, diagnosis, and treatment of maternal and fetal disease through: support for the clinical practice of maternal-fetal medicine; research; education/training; advocacy; health policy leadership. Since 1980 the Society has annually hosted educational meetings at which peer-reviewed research and postgraduate courses (...) (GR) Committee and engage more actively newer members of the Society who are interested in GR. As part of this, SMFM has developed an Advocacy Guidebook for members so that anyone can learn more about advocacy and how to be an effective advocate. SMFM is also the leading voice in an effort to improve information on drugs that women may need during pregnancy and lactation. With more women of advanced maternal age getting pregnant and the increasing rates of chronic disease in the general population

2015 Society for Maternal-Fetal Medicine

100. Contraception after pregnancy. (Abstract)

that this may not necessary, at least for healthy women <35 years old. Most contraceptive methods can be used after pregnancy regardless of the outcome. Because of an increased risk of venous thromboembolism associated with estrogen-containing contraceptives initiation of these methods should be delayed until 6 weeks after childbirth. More research is required to settle the questions over the use of combined hormonal contraception during breastfeeding, the use of injectable progestin-only contraceptives (...) before 6 weeks after childbirth and use of both hormonal and intrauterine contraception after gestational trophoblastic disease. The potential impact on the risk of ectopic pregnancy of certain contraceptive methods often confuses healthcare providers. The challenges involved in providing effective, seamless service provision of contraception after pregnancy are numerous, even in industrialised countries. Nevertheless, the clear benefits demonstrate that it is worth the effort. This article

2019 Acta Obstetricia et Gynecologica Scandinavica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>